Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$231.4M
23M shares
52-week range
$3.65 – $10.99
88% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
1.52%
Moderate
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $30.3M | $40.9M | $108.1M | $209.8M | $157.1M | $146.0M | $145.2M | $146.1M |
| Cost of revenue | $161.4M | $2.4M | $2.7M | $3.4M | $5.2M | $4.9M | $6.0M | $5.9M |
| Gross profit | −$131.0M | $38.5M | $105.4M | $206.4M | $151.9M | $141.1M | $139.2M | $140.1M |
| Gross margin | -431.9% | 94.1% | 97.5% | 98.4% | 96.7% | 96.6% | 95.9% | 95.9% |
| R&D | $161.4M | $122.3M | $150.8M | $160.8M | $148.7M | $138.8M | $143.2M | $125.6M |
| Operating income | −$179.9M | −$189.3M | −$171.8M | −$98.3M | −$142.2M | −$129.5M | −$119.4M | −$90.7M |
| EBITDA | −$175.2M | −$182.9M | −$167.9M | −$97.0M | −$139.3M | −$118.4M | −$38.6M | −$149.9M |
| Net income | −$178.4M | −$199.6M | −$196.3M | −$124.1M | −$165.3M | −$143.1M | −$76.4M | −$196.0M |
| Net margin | -588.1% | -488.1% | -181.6% | -59.1% | -105.2% | -98.0% | -52.6% | -134.2% |
| EPS (diluted) | -47.11 | -48.32 | -40.87 | -24.75 | -30.28 | -18.79 | -9.41 | -17.93 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $137M | $-4.08 | $-4.17–$-3.99 | 3 |
| 2027 | $155M | $-3.12 | $-3.52–$-2.78 | 2 |
| 2028 | $230M | $-1.54 | $-3.45–$-0.56 | 3 |
| 2029 | $418M | $1.49 | $1.33–$1.69 | 1 |
Forward consensus · source: Financial Modeling Prep
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
www.karyopharm.comNo one on the platform currently holds KPTI.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 105,414 | $587.2K |
| Execution date | Ratio |
|---|---|
| 2025-02-26 | 1-for-15reverse |
No one on the platform has traded KPTI yet.
| $37M |
| — |
| INMBINmune Bio, Inc. | $1.62 | +14.08% | $43M | — |
| MDCXMedicus Pharma Ltd. Common Stock | $0.49 | +6.51% | $11M | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 0.7× sales vs its 1.7× historical median P/S.
Fair value ≈ $23.02 · price $10.09 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$KPTI lol Ipsen bought Kartos and not Karyopharm? How come CEO Richard Paulson and Karyopharm’s BD team couldn’t get that deal? Uncle Rolli and I could tell you why… we are focused on fixing biotechs, not just selling them on the cheap because private companies are often more poorly run than publicly traded ones. 🏦 $SLS $CCCC and $ALLR ALL DAY over the Krazy Pharm of Newton Massachusetts 😂
View on StockTwits ↗$ALLR $CCCC $KPTI $INCY hmm who will Incyte buy next? 💊 Vega Therapeutics will not sustain them for long … will it? 🤔
View on StockTwits ↗$KPTI options are dead. Zero speculation of success being traded on. But also no bearish trades. Just dead. Nobody's counting on this horrible CEO to be able to pull it off, even with good data. He's even fuck up the best data - look at his lousy track record: 5 years of fucking up KPTI - destroying it by over 95% as himself and the lousy Board and Mike Mano et al were paid millions. A CEO like that turning around a company? No chance. And he has no turnaround experience in his weak resume. Firing him is wha the Board should have done 4 years ago. But they don't give a shit as long as those fucking direct deposits keep coming. Just opinions based on known facts.
View on StockTwits ↗$KPTI We're stuck at fucking 60 cents down from 25 (pre-RS units) or $9 down from $375 due to this lousy CEO and Board who've gotten richer and richer at our cost while company value has been destroyed due to their lameass shit mismanagement of the company. Winners: Richard Paulson, Barry Greene and the rest of that useless irresponsible Board, short sellers, Dempsey and other receiver of the money these clowns gave away. Losers: anybody who trusted this lousy CEO, Board, their lousy General Council and lousy ex-CFO and ex-Board members who are all responsible for this mess, and all made millions. Our only option: holding these clowns accountable and liable, legally, for every penny they got: Karma is a bitch.
View on StockTwits ↗$KPTI 375,000 share trade at 9.20. That's 5.6m shares pre-RS. Every year Richard Paulson and the horrible irresponsible Board have further damaged the company value, while they paid themseleves fat salaries and bonuses and shorts have made a ton of money too - at our cost.
View on StockTwits ↗$KPTI 80 fucking million shorted shares (pre-RS unit) betting against horrible CEO&BoD. Latest short interest: 5,348,401 (per-RS unit). This foolish, incompetent CEO and the useless, irresponsible BoD think they can turn KPTI around after destroying it. Sad for them: no cash left to cover their legal liability; they'll have to fund that themselves. They have plenty of money - for us - after years of getting our money and doing diddly squat that ever translated to value - except for the short sellers who love'em. Paulson still thinks he has 3 shots on the goal - with no cash any more since he splurged it all on that useless, unproductive, wasteful, entitled, lazy, vacation club style "culture" he's so fucking proud of - funded by us. But miracles do rarely happen so let's see. But the best of data, Paulson, Mano et al. will screw it that up too. And if it translates to money, it seems Paulson will make sure shareholders don't see any: he'd rather give it to Dempsey et al. - IMHO
View on StockTwits ↗$KPTI 2 big blocks dumped at the close. I guess someone's seeing through Paulson's three shots of the goaln delusional BS talk. He's been giving us BS talk for over 5 fucking years as he's gotten paid millions despite having destroyed KPTI with his bullshit mismanagement and playing fucking Russian Roulette with the money he was entrusted with to create value - he splurged instead.
View on StockTwits ↗$KPTI The useless Board should have fired Paulson's ass years ago. Instead it cost us a hundreds of millions in value, and the Board and Paulson got paid millions. Paulson will never be able to take Karyopharm to the next level - even with the best of data. He proves that point time and again. Resign Richard. It's almost too late. Our future now depends on one binary event but Paulson seems triple vision, and never sees money as an issue as long as he has shareholders to dilute.
View on StockTwits ↗$KPTI Paulson's ignorant stupid BS answer to biotech reporter at EHA.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.